Covered recipient · General Payments record
LARRY ZHAO
Allopathic & Osteopathic Physicians Pathology Anatomic Pathology & Clinical Pathology
General Payments · PY2023–2024
$30,072.71
- Reported across 28 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $19,461.44 | 18 |
| Food and Beverage | $16.71 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| CSL Plasma Inc. | $19,461.44 | 18 |
| Roche Diagnostics Corporation | $16.71 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| CSL Plasma Inc. | $1,688.64 | 01/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660755 | CMS |
| CSL Plasma Inc. | $888.64 | 01/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660759 | CMS |
| CSL Plasma Inc. | $568.64 | 01/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660757 | CMS |
| CSL Plasma Inc. | $568.64 | 01/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660761 | CMS |
| CSL Plasma Inc. | $728.64 | 02/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660763 | CMS |
| CSL Plasma Inc. | $1,848.64 | 02/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660765 | CMS |
| CSL Plasma Inc. | $888.64 | 03/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660767 | CMS |
| CSL Plasma Inc. | $888.64 | 03/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660769 | CMS |
| CSL Plasma Inc. | $2,008.64 | 03/15/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660771 | CMS |
| CSL Plasma Inc. | $1,048.64 | 03/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660773 | CMS |
| CSL Plasma Inc. | $1,208.64 | 04/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660775 | CMS |
| CSL Plasma Inc. | $541.60 | 04/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660777 | CMS |
| CSL Plasma Inc. | $888.64 | 05/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660779 | CMS |
| CSL Plasma Inc. | $2,008.64 | 05/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660781 | CMS |
| CSL Plasma Inc. | $1,048.64 | 05/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660783 | CMS |
| CSL Plasma Inc. | $1,208.64 | 05/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660785 | CMS |
| CSL Plasma Inc. | $541.60 | 05/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660787 | CMS |
| CSL Plasma Inc. | $888.64 | 05/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1134660789 | CMS |
| Roche Diagnostics Corporation | $16.71 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089611228 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.